Table 1

Characteristics of patients and controls.

Characteristics

Number (%) or mean (range)


HC

(n = 30)

AAV


Remission

(n = 37)

Activea

(n = 5)

Activeb

(n = 18)


Male

17 (57)

25 (68)

3 (60)

14 (78)

Age (years)

45 (28-64)

57 (26-84)

58 (47-68)

58 (32-81)

Diagnosis

GPA

26

4

13

MPA

9

1

5

NCGN

2

0

0

ANCA-specificity

PR3

24 (65)

4 (80)

13 (72)

MPO

13 (35)

1 (20)

5 (28)

Organ involvement

ENT

0

4 (80)

5 (28)

Eye

0

1 (20)

4 (22)

Lung

0

4 (80)

8 (44)

Kidney

0

2 (40)

13 (72)

Skin

0

1 (20)

0

Nervous system

0

1 (20)

2 (11)

BVAS, median (range)

0

14.8 (6-26)

17.5 (6-33)

Treatment

MMF

0

1 (20)

3 (17)

CYC

0

4 (80)

11 (61)

Prednisolon

0

4 (80)

16 (89)


AAV, ANCA-associated vasculitides; ANCA, anti-neutrophil cytoplasmic autoantibody; BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide; ENT, ear, nose and throat; GPA, granulomatosis with polyangiitis; HC, healthy control; MMF, mycophenolate mophetil; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NCGN, necrotizing crescentic glomerulonephritis; PR3, proteinase 3; aActive patients included in CXCR1 and CXCR2 measurement by flow cytometry. bActive patients included in cytokine profiling by ELISA.

Hu et al. Arthritis Research & Therapy 2011 13:R201   doi:10.1186/ar3534

Open Data